ISPOR - EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Switzerland

Full Text

EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Switzerland

Abstract

Authors

C Oniangue-Ndza F Kamgar RP Schneider S Teitsson C Knight

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now